SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SPRO

Spero Therapeutics, Inc. (NASDAQ:SPRO)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.74-$0.08 (-10.20%)
 
Market cap
$43.2M
Insider Score
Analyst consensus
Listed since
Nov 2, 2017
Market Cap$43.23M-68.8%
Revenue (ttm)n/a+11.6%
Net Incomen/a+32.7%
EPSn/a+35.0%
Shares Out58.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume424,809
Open$0.80
Previous Close$0.83
Day's Range$0.74 - $0.81
52-Week Range$0.73 - $3.08
Beta1.56
AnalystsBuy
Price Targetn/a
Earnings Daten/a

About SPRO

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Address
675 Massachusetts Avenue, Cambridge, MA, 02139, US
Market Cap
43 million
Employees
25
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$594.53K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating SPRO in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-10.20%
5 Days
-25.05%
1 Month
-34.34%
6 Months
-73.12%
1 Year
-68.82%

$SPRO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SPRO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SPRO's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SPRO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New SPRO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SPRO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in SPRO

VTIVanguard Morningstar Total Stock Market ETF$1.17M
VXFVanguard Extended Market ETF$628.85K
IWCiShares Micro-Cap ETF$113.43K
GISCGuggenheim Funds Trust - Guggenheim Securitized Income ETF$112.89K
QQQSInvesco NASDAQ Future Gen 200 ETF$81.97K
PRFZInvesco RAFI US 1500 Small-Mid ETF$55.16K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from SPRO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
85
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
10
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.47%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.05%
GISCGuggenheim Funds Trust - Guggenheim Securitized Income ETF0.01%

Weight is the stock’s share of each fund’s holdings.